NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $6.92 +1.58 (+29.59%) As of 05/26/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Predictive Oncology Stock (NASDAQ:POAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Predictive Oncology alerts:Sign Up Key Stats Today's Range$5.40▼$7.2050-Day Range$1.41▼$8.7552-Week Range$0.71▼$16.54Volume1.24 million shsAverage Volume473,545 shsMarket Capitalization$23.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Predictive Oncology, Inc. is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines. The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells. This platform is complemented by proprietary data integration tools that correlate cellular phenotypes with genetic and molecular profiles. Predictive Oncology also provides custom assay development and contract research services to pharmaceutical and biotech partners seeking to validate drug mechanisms, optimize dosing regimens, or identify novel targets in oncology and related therapeutic areas. Headquartered in St. James, New York, Predictive Oncology serves a global customer base that includes large pharmaceutical companies, emerging biotechs, and academic research institutions. The company began trading on the Nasdaq Capital Market under the ticker POAI in December 2020. Its leadership team brings together expertise in computational biology, oncology research, and data science, positioning Predictive Oncology at the intersection of cutting-edge technology and translational cancer research.AI Generated. May Contain Errors. Read More Predictive Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScorePOAI MarketRank™: Predictive Oncology scored higher than 1% of companies evaluated by MarketBeat, and ranked 865th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingPredictive Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePredictive Oncology has received no research coverage in the past 90 days.Read more about Predictive Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Predictive Oncology is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Predictive Oncology is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for POAI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for POAI on MarketBeat in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders1.21% of the stock of Predictive Oncology is held by insiders.Percentage Held by Institutions9.04% of the stock of Predictive Oncology is held by institutions.Read more about Predictive Oncology's insider trading history. Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. POAI Stock News HeadlinesPredictive Oncology announces name change to Axe ComputeDecember 12, 2025 | msn.comPredictive Oncology rebrands to Axe Compute Inc.December 11, 2025 | msn.comMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent traveled to Lower Manhattan for a sit-down interview with 60-year Wall Street legend Marc Chaikin, she was shocked to discover that Marc had prepared a live demonstration of a technology that could change society forever. It involves NASA, the Department of Defense, huge banks – and a MAJOR AI upgrade that could add $400 trillion to the global economy. | Chaikin Analytics (Ad)Predictive Oncology Regains Nasdaq ComplianceDecember 2, 2025 | tipranks.comPredictive Oncology regains compliance with Nasdaq minimum stockholder equityDecember 2, 2025 | msn.comPredictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementDecember 2, 2025 | markets.businessinsider.comPredictive Oncology Regains Nasdaq Compliance with InvestmentsNovember 20, 2025 | tipranks.comPredictive Oncology Expands into Digital Asset ManagementNovember 20, 2025 | msn.comSee More Headlines POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $7.15 at the beginning of the year. Since then, POAI stock has decreased by 3.2% and is now trading at $6.92. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings data on Friday, November, 14th. The medical instruments supplier reported ($4.52) EPS for the quarter, missing the consensus estimate of ($1.35) by $3.17. The medical instruments supplier earned $0 million during the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative trailing twelve-month return on equity of 732.73% and a negative net margin of 5,065.23%. Read the conference call transcript. When did Predictive Oncology's stock split? Predictive Oncology shares reverse split on Tuesday, September 30th 2025.The 1-15 reverse split was announced on Thursday, September 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W). Company Calendar Last Earnings11/14/2025Today5/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:POAI CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees30Year Founded2002Profitability EPS (Trailing Twelve Months)($13.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.66 million Net Margins-5,065.23% Pretax Margin-5,082.34% Return on Equity-732.73% Return on Assets-235.55% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual Sales$1.66 million Price / Sales14.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.46) per share Price / Book-15.04Miscellaneous Outstanding Shares3,394,000Free Float3,353,000Market Cap$23.49 million OptionableNot Optionable Beta1.35 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:POAI) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredThe AI Shakeout Is Coming — Most Investors Won’t SurviveEvery major tech shift follows the same pattern: hype, a brutal shakeout, then a handful of winners that take ...Prosperity Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free POAI Stock Alerts